Security
ImmunityBio, Inc. Common Stock · IBRX
IBRXNASDAQCommon stockCurrentCIK 1326110Updated Oct 4, 2026
Name history
NantKwest, Inc. · through Mar 8, 2021Conkwest, Inc. · through Jul 13, 2015ZelleRx Corp · through Oct 9, 2009
IBRX price & chart
Loading TradingView…
NASDAQ:IBRX on TradingView ↗About the company
ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of our strategy is the Cancer BioShield™ platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via our proprietary IL-15 superagonist. Our Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by an investigational portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy. For more information, visit ImmunityBio.com and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram.
In the news
These High-Voltage Stocks Are Suddenly Impossible to Ignore ↗
INVESTOR DEADLINE TUESDAY: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX ↗
Recent filings
SCHEDULE 13D/A - filed by Cambridge Equities, LP regarding ImmunityBio, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
144 filing
Show 5 more recent filings
144 filing
144 filing
144 filing
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 501,898,000Source | 382,933,000Source | 504,452,000Source | 362,356,000Source |
| Property, Plant and Equipment, NetUSD | 114,264,000Source | 137,094,000Source | 146,082,000Source | 143,659,000Source |
| GoodwillUSD | 910,000Source | 910,000Source | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | 17,093,000Source | 20,003,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 88,334,000Source | 143,428,000Source | 265,453,000Source | 104,641,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 42,571,000Source | 2,360,000Source | — | — |
| Inventory, NetUSD | 910,000Source | 8,272,000Source | — | — |
| Assets, CurrentUSD | 314,875,000Source | 184,586,000Source | 294,084,000Source | 140,577,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 28,530,000Source | 23,852,000Source | 25,603,000Source | 31,503,000Source |
| Operating Lease, Right-of-Use AssetUSD | 33,010,000Source | 33,363,000Source | 36,543,000Source | 45,788,000Source |
| Other Assets, NoncurrentUSD | — | 4,827,000Source | 2,880,000Source | 4,860,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,001,472,000Source | 871,062,000Source | 1,090,389,000Source | 812,176,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 101,000Source | 85,000Source | 67,000Source | 42,000Source |
| Retained Earnings (Accumulated Deficit)USD | -3,726,646,000Source | -3,375,248,000Source | -2,961,684,000Source | -2,378,488,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 28,956,000Source | 1,198,000Source | 10,000Source | 183,000Source |
| Stockholders' Equity Attributable to ParentUSD | -500,469,000Source | -489,098,000Source | -586,987,000Source | -447,327,000Source |
| Additional Paid in Capital, Common StockUSD | 3,197,120,000Source | 2,884,867,000Source | 2,374,620,000Source | 1,930,936,000Source |
| Liabilities and EquityUSD | 501,898,000Source | 382,933,000Source | 504,452,000Source | 362,356,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 61,754,000Source | 54,944,000Source | 58,283,000Source | 500,861,000Source |
| Operating Lease, Liability, CurrentUSD | 7,535,000Source | 7,466,000Source | 5,244,000Source | 2,650,000Source |
| Accounts Payable, CurrentUSD | — | — | — | 21,016,000Source |
| Operating Lease, Liability, NoncurrentUSD | 33,447,000Source | 34,823,000Source | 39,942,000Source | 47,951,000Source |
| Other Liabilities, NoncurrentUSD | 424,000Source | 639,000Source | 1,109,000Source | 457,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 895,000Source | 969,000Source | 1,050,000Source | -2,493,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 46,838,000Source | 40,580,000Source | 42,708,000Source | 41,825,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 139,000Source | 148,000Source | 158,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -351,472,000Source | -413,645,000Source | -583,852,000Source | -417,320,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 15,525,000Source | 17,554,000Source | 18,512,000Source | 18,260,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 36,809,000Source | 34,432,000Source | 49,163,000Source | 40,179,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 40,211,000Source | 2,360,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | 6,325,000Source | 8,272,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | -139,000Source | — | — | -4,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -304,936,000Source | -391,236,000Source | -366,757,000Source | -337,509,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -149,801,000Source | -12,246,000Source | -30,470,000Source | 27,297,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 3,846,000Source | 6,888,000Source | 30,584,000Source | 78,162,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 2,265,000Source | 5,465,000Source | 3,443,000Source | 616,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 400,241,000Source | 281,630,000Source | 558,341,000Source | 233,613,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -54,481,000Source | -121,875,000Source | 160,822,000Source | -76,315,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 71,321,000Source | 92,318,000Source | 77,192,000Source | 35,442,000Source |
| Income Taxes Paid, NetUSD | 0Source | 15,000Source | 8,000Source | 2,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 36,809,000Source | 34,432,000Source | 49,163,000Source | 40,179,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 0Source | 22,587,000Source | 42,396,000Source | 16,282,000Source |
| Amortization of Intangible AssetsUSD | — | 2,000,000Source | 2,000,000Source | — |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | 0Source | -632,000Source | -1,591,000Source | -4,190,000Source |
| DepreciationUSD | 13,400,000Source | 15,500,000Source | 16,500,000Source | 16,300,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | 6,398,000Source | 13,477,000Source | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | 0Source | -632,000Source | -1,591,000Source | -4,190,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | -42,773,000Source | 43,472,000Source | -36,203,000Source | — |
| Gain (Loss) on InvestmentsUSD | 6,405,000Source | 7,975,000Source | 1,131,000Source | -3,090,000Source |
| GoodwillUSD | 910,000Source | 910,000Source | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 0Source | 0Source | 886,000Source | 681,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 0Source | 0Source | -7,549,000Source | -12,107,000Source |
| Income Tax Expense (Benefit)USD | -135,000Source | 0Source | -40,000Source | 34,000Source |
| Net Income (Loss) Attributable to ParentUSD | -351,398,000Source | -413,564,000Source | -583,196,000Source | -416,567,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -74,000Source | -81,000Source | -656,000Source | -753,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -351,398,000Source | -413,564,000Source | — | — |
| Nonoperating Income (Expense)USD | -95,580,000Source | -69,463,000Source | -221,642,000Source | -65,988,000Source |
| Operating ExpensesUSD | — | 358,927,000Source | 362,872,000Source | 351,538,000Source |
| Other Nonoperating Income (Expense)USD | -2,174,000Source | -15,000Source | -2,223,000Source | -736,000Source |
| Proceeds from Contributions from AffiliatesUSD | — | — | 0Source | 0Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 60,427,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 64,897,000Source | 115,586,000Source | 10,100,000Source | 128,188,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | 294,000Source | 74,000Source |
| Realized Investment Gains (Losses)USD | -292,000Source | -42,000Source | 15,000Source | -122,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | -59,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 113,288,000Source | 14,745,000Source | 622,000Source | 240,000Source |
| Cost of RevenueUSD | 753,000Source | 0Source | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | 168,783,000Source | 129,620,000Source | 102,708,000Source |
| Operating Income (Loss)USD | -256,027,000Source | -344,182,000Source | -362,250,000Source | -351,298,000Source |
| Other Nonoperating Income (Expense)USD | -2,174,000Source | -15,000Source | -2,223,000Source | -736,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -351,607,000Source | -413,645,000Source | -583,892,000Source | -417,286,000Source |
| Income Tax Expense (Benefit)USD | -135,000Source | 0Source | -40,000Source | 34,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -74,000Source | -81,000Source | -656,000Source | -753,000Source |
| Net Income (Loss) Attributable to ParentUSD | -351,398,000Source | -413,564,000Source | -583,196,000Source | -416,567,000Source |
| Earnings Per Share, BasicUSD per share | -0.38Source | -0.59Source | -1.15Source | -1.04Source |
| Earnings Per Share, DilutedUSD per share | -0.38Source | -0.62Source | -1.15Source | -1.04Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 919,863,000Source | 697,312,000Source | 508,635,592Source | 399,900,374Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 919,863,000Source | 700,443,000Source | 508,635,592Source | 399,900,374Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | 2,000,000Source | 2,000,000Source | — |
| Costs and ExpensesUSD | 369,315,000Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | 4,000Source | 0Source | -26,000Source | 38,000Source |
| Debt and Equity Securities, Unrealized Gain (Loss)USD | 0Source | -632,000Source | -1,591,000Source | -4,190,000Source |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | -42,773,000Source | 43,472,000Source | -36,203,000Source | — |
| Gain (Loss) on InvestmentsUSD | 6,405,000Source | 7,975,000Source | 1,131,000Source | -3,090,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -348,393,000Source | -410,458,000Source | -581,136,000Source | -413,653,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 0Source | 0Source | -7,549,000Source | -12,107,000Source |
| Interest and Other IncomeUSD | 2,689,000Source | 2,400,000Source | 863,000Source | 2,708,000Source |
| Interest ExpenseUSD | 60,886,000Source | 114,670,000Source | 129,198,000Source | 63,515,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -351,398,000Source | -413,564,000Source | — | — |
| Nonoperating Income (Expense)USD | -95,580,000Source | -69,463,000Source | -221,642,000Source | -65,988,000Source |
| Operating ExpensesUSD | — | 358,927,000Source | 362,872,000Source | 351,538,000Source |
| Realized Investment Gains (Losses)USD | -292,000Source | -42,000Source | 15,000Source | -122,000Source |
| Research and Development ExpenseUSD | — | 190,144,000Source | 232,366,000Source | 248,149,000Source |
Filing attachments
d75270dex991.htm · 8-K · 2026-05-18
EX-99.1 2 d75270dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tokyo strain of BCG (Tokyo-172 BCG) versus TICE BCG in BCG-naïve high-grade non-muscle invasive bladder cancer ImmunityBio to serve as sole U.S.…
Read attachment ↗d70606dex991.htm · 8-K · 2026-04-06
EX-99.1 2 d70606dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance Company initiated a comprehensive review of promotional materials and is implementing enhanced advertising compliance measures, including expanded promotional review protocols, executive training, and external regulatory oversight Company has removed the identified podcast from its corporate website and formally requested …
Read attachment ↗d139829dex991.htm · 8-K · 2026-03-31
EX-99.1 3 d139829dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline ImmunityBio to receive $75 million in non-dilutive funding under existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital, bringing total committed capital to $375 million Simultaneously con…
Read attachment ↗d29656dex991.htm · 8-K · 2025-08-08
EX-99.1 2 d29656dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA IN RE IMMUNITYBIO, INC. NOTICE OF PROPOSED DERIVATIVE SHAREHOLDER SETTLEMENT DERIVATIVE LITIGATION Lead Case No.: 3:24-cv-02014-GPC-VET (Consolidated with 3:25-cv-00416-GPC-VET 3:25-cv-00423-GPC-VET) …
Read attachment ↗d29656dex992.htm · 8-K · 2025-08-08
EX-99.2 3 d29656dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA IN RE IMMUNITYBIO, INC. STIPULATION AND SETTLEMENT AGREEMENT SHAREHOLDER DERIVATIVE LITIGATION Lead Case No.: 3:24-cv-02014-GPC-VET (Consolidated with 3:25-cv-00416-GPC-VET 3:25-cv-00…
Read attachment ↗d20571dex41.htm · 8-K · 2025-07-25
EX-4.1 3 d20571dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 COMMON STOCK PURCHASE WARRANT IMMUNITYBIO, INC. Warrant Shares: Issue Date: July __, 2025 ────────────────────────────────────────────────── THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _______________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Dat…
Read attachment ↗